Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (151-160 of 459) with videos related to

Pageof 46
Sort By:
Expert Review of Anticancer Therapy|May 15, 2023
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancerGiacomo Nuvola, Matteo Santoni, Mimma Rizzo, et al.
Immunotherapy|November 27, 2018
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysisMatteo Santoni, Alessandro Conti, Sebastiano Buti, et al.
Current Drug Targets|December 10, 2015
An Overview of Emerging Immunotargets of Genitourinary TumorsRodolfo Montironi, Matteo Santoni, Liang Cheng, et al.
Biomed Research International|June 28, 2014
CXC and CC chemokines as angiogenic modulators in nonhaematological tumorsMatteo Santoni, Sergio Bracarda, Massimo Nabissi, et al.
Current Oncology (Toronto, Ont.)|July 26, 2024
Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant SettingHalima Abahssain, Amine Souadka, Rania Alem, et al.
Current Drug Metabolism|February 26, 2019
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to TherapyAlessia Cimadamore, Marina Scarpelli, Matteo Santoni, et al.
Recenti Progressi in Medicina|May 22, 2015
[Treatment of pancreatic cancer. Actuality and perspective]Alessandro Bittoni, Kalliopi Andrikou, Andrea Lanese, et al.
Cancer Treatment Reviews|September 28, 2013
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trialsRoberto Iacovelli, Daniele Alesini, Antonella Palazzo, et al.
Frontiers in Oncology|January 10, 2018
Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 ExpressionAlessia Cimadamore, Silvia Gasparrini, Roberta Mazzucchelli, et al.
European Urology|March 8, 2016
Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4Francesco Piva, Matteo Santoni, Marina Scarpelli, et al.
Pageof 46

Showing results (151-160 of 459) with videos related to

Sort By:
Pageof 46
Expert Review of Anticancer Therapy|May 15, 2023
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancerGiacomo Nuvola, Matteo Santoni, Mimma Rizzo, et al.
Immunotherapy|November 27, 2018
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysisMatteo Santoni, Alessandro Conti, Sebastiano Buti, et al.
Current Drug Targets|December 10, 2015
An Overview of Emerging Immunotargets of Genitourinary TumorsRodolfo Montironi, Matteo Santoni, Liang Cheng, et al.
Biomed Research International|June 28, 2014
CXC and CC chemokines as angiogenic modulators in nonhaematological tumorsMatteo Santoni, Sergio Bracarda, Massimo Nabissi, et al.
Current Oncology (Toronto, Ont.)|July 26, 2024
Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant SettingHalima Abahssain, Amine Souadka, Rania Alem, et al.
Current Drug Metabolism|February 26, 2019
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to TherapyAlessia Cimadamore, Marina Scarpelli, Matteo Santoni, et al.
Recenti Progressi in Medicina|May 22, 2015
[Treatment of pancreatic cancer. Actuality and perspective]Alessandro Bittoni, Kalliopi Andrikou, Andrea Lanese, et al.
Cancer Treatment Reviews|September 28, 2013
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trialsRoberto Iacovelli, Daniele Alesini, Antonella Palazzo, et al.
Frontiers in Oncology|January 10, 2018
Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 ExpressionAlessia Cimadamore, Silvia Gasparrini, Roberta Mazzucchelli, et al.
European Urology|March 8, 2016
Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4Francesco Piva, Matteo Santoni, Marina Scarpelli, et al.
Pageof 46